Loading...
LRMR logo

Larimar Therapeutics, Inc.NasdaqGM:LRMR Stock Report

Market Cap US$404.1m
Share Price
US$3.89
US$15.88
75.5% undervalued intrinsic discount
1Y108.0%
7D-2.8%
Portfolio Value
​
View

Larimar Therapeutics, Inc.

NasdaqGM:LRMR Stock Report

Market Cap: US$404.1m

Larimar Therapeutics (LRMR) Stock Overview

A clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. More details

LRMR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Earnings are forecast to grow 56.56% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months compared to the US market

Shareholders have been substantially diluted in the past year


LRMR Community Fair Values

Create Narrative

See what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Larimar Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Larimar Therapeutics
Historical stock prices
Current Share PriceUS$3.89
52 Week HighUS$6.42
52 Week LowUS$1.73
Beta0.91
1 Month Change-20.12%
3 Month Change23.49%
1 Year Change108.02%
3 Year Change3.18%
5 Year Change-71.04%
Change since IPO-68.37%

Recent News & Updates

Analysis Article • Jan 24

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jan 16

Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care

Summary Larimar Therapeutics is deeply undervalued, trading at ~$3.40 despite a de-risked safety profile and a clear regulatory path for its lead asset. Nomlabofusp directly addresses Friedreich’s Ataxia’s root cause, with a mechanism that delivers missing frataxin, potentially supplanting current standard-of-care. Anaphylaxis concerns have been mitigated by new dosing protocols and FDA-approved trial modifications, positioning LRMR for a potential re-rating. With $175.4m cash runway into Q4-26 and multiple near-term catalysts, LRMR offers asymmetric risk-reward, targeting a 3-5x return if milestones are met. Read the full article on Seeking Alpha

Recent updates

Analysis Article • Jan 24

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jan 16

Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care

Summary Larimar Therapeutics is deeply undervalued, trading at ~$3.40 despite a de-risked safety profile and a clear regulatory path for its lead asset. Nomlabofusp directly addresses Friedreich’s Ataxia’s root cause, with a mechanism that delivers missing frataxin, potentially supplanting current standard-of-care. Anaphylaxis concerns have been mitigated by new dosing protocols and FDA-approved trial modifications, positioning LRMR for a potential re-rating. With $175.4m cash runway into Q4-26 and multiple near-term catalysts, LRMR offers asymmetric risk-reward, targeting a 3-5x return if milestones are met. Read the full article on Seeking Alpha
Analysis Article • May 28

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jan 03

Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better

Summary Larimar Therapeutics, Inc. reported initial positive data from phase 2 long-term OLE study using nomlabofusp for treatment of patients with Friedreich's Ataxia; Increase of tissue FXN protein levels from 15% to 30%. The global Friedreich's Ataxia market size is projected to reach $2.06 billion by 2030. Additional data using higher 50 mg dose of nomlabofusp to treat patients with Friedreich's Ataxia expected in mid-2025. Accelerated Approval BLA filing of nomlabofusp for patients with Friedreich's Ataxia might be possible 2nd half of 2025 on basis of a surrogate biomarker endpoint of FXN protein levels. Read the full article on Seeking Alpha
Analysis Article • Dec 18

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Oct 07

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Summary Larimar Therapeutics' CTI-1601, a potential first-in-class treatment for Friedreich's ataxia, shows promise in modifying disease progression and restoring mitochondrial function. The company has a solid cash runway, sufficient liquidity, and trades at reasonable valuations compared to its upside potential. LRMR's favorable Phase 1/2 trial results bolster CTI-1601's approval odds, with a potential Biologics License Application submission by 2H2025. Additionally, CTI-1601 has multiple FDA and EU designations, potentially expediting its development and approval process. Despite competition risks, LRMR's unique approach and sufficient resources make it a speculative "Buy" for investors aware of inherent biotech risks. Read the full article on Seeking Alpha
Analysis Article • Aug 09

Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 15

Larimar Therapeutics: More Data Still Needed

Summary Larimar Therapeutics' stock has surged 50% after its FA therapy was selected for FDA's START program, aiming for a BLA filing in 2H25. Its lead candidate Nomlabofusp is a protein replacement therapy for Friedreich's ataxia, competing with Biogen's Skyclarys and other potential treatments. Larimar has enough cash to fund operations until 2026, with analyst optimism and a timeline to potentially beat competitors to the market. Can the recent rally in the shares continue? A full investment analysis follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • May 31

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

Summary Partial clinical hold from FDA, for use of nomlabofusp for the treatment of patients with Friedreich's Ataxia completely lifted; higher dosing of 50 mg of treatment now possible. It is expected that the global Friedreich's Ataxia market could reach $2.06 billion by 2030. Interim data from the ongoing phase 2 open-label study, using nomlabofusp for the treatment of patients with Friedreich's Ataxia, expected Q4 of 2024. Nomlabofusp for the treatment of patients with Friedreich's Ataxia selected as part of the FDA pilot program known as START, which is intended to accelerate the development of drugs that target rare unmet medical needs. Read the full article on Seeking Alpha
Analysis Article • Nov 13

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 19

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Feb 02

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 20

Laramar Therapeutics issued patent for lead pipeline candidate

Larimar Therapeutics (NASDAQ:LRMR) has been granted a composition of matter patent covering CTI-1601, its lead pipeline candidate for Friedreich’s ataxia. The patent provides coverage through at least July 2040. CTI-1601, currently in phase 1, has Fast Track and Orphan Drug designation from the US FDA. The company plans to begin a phase 2 trial for CTI-1601 by the end of the year. Seeking Alpha's Quant Rating views Larimar (LRMR) as a strong buy with high marks for momentum and revisions.
Seeking Alpha • Sep 14

Larimar Therapeutics prices ~$70M stock offering

Larimar Therapeutics (NASDAQ:LRMR) has priced of an underwritten offering of 22,225,000 shares of common stock at $3.15 per share. Underwriters have been granted a 30-day overallotment option to purchase up to 3,333,750 additional shares of common stock at the offering price. Gross proceeds to Larimar (LRMR) are expected to be ~$70M. The offering is expected to close around Sep 16, 2022. The biotech company also received FDA clearance to initiate the 25mg cohort of a Phase 2 Dose exploration trial of its lead compound, CTI-1601, in Friedreich's ataxia patients. It plans to begin the Phase 2 trial in Q4 2022, with top-line data expected in 2H 2023. CTI-1601 is a recombinant fusion protein intended to deliver human frataxin to the mitochondria of patients with Friedreich's ataxia who are unable to produce enough of this essential protein. LRMR shares have gained 2% pre-market on the news
Analysis Article • Sep 02

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 11

Larimar Therapeutics GAAP EPS of -$0.47

Larimar Therapeutics press release (NASDAQ:LRMR): Q2 GAAP EPS of -$0.47. Cash and marketable debt securities at June 30, 2022 of $54.9 million provides projected cash runway through the third quarter of 2023
Analysis Article • Mar 21

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 18

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Feb 08

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

LRMRUS BiotechsUS Market
7D-2.8%1.0%1.1%
1Y108.0%40.3%26.7%

Return vs Industry: LRMR exceeded the US Biotechs industry which returned 44.4% over the past year.

Return vs Market: LRMR exceeded the US Market which returned 25.4% over the past year.

Price Volatility

Is LRMR's price volatile compared to industry and market?
LRMR volatility
LRMR Average Weekly Movement21.5%
Biotechs Industry Average Movement10.7%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.1%

Stable Share Price: LRMR's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: LRMR's weekly volatility has increased from 16% to 22% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a71Carole Ben-Maimonwww.larimartx.com

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics, Inc. Fundamentals Summary

How do Larimar Therapeutics's earnings and revenue compare to its market cap?
LRMR fundamental statistics
Market capUS$404.10m
Earnings (TTM)-US$166.00m
Revenue (TTM)n/a
0.0x
P/S Ratio
-2.4x
P/E Ratio

Is LRMR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LRMR income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$166.01m
Earnings-US$166.00m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-1.60
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did LRMR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/14 00:15
End of Day Share Price 2026/05/14 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Larimar Therapeutics, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
null nullBaird
Christopher ChenBaird